For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Efficacy > Metastatic BRAF V600+ Melanoma > Overall Survival
For first-line targeted therapy in patients with BRAF V600 positive metastatic melanoma 

Give patients the opportunity for extended survival1*

Across COMBI-d and COMBI-v, more than one-third of patients in the intent-to-treat population were alive at 5 years1

pooled-os-5-year-itt-population-desktop-2x


In the pooled analysis of COMBI-d/v, more than half of patients with low tumor burden were alive at 5 years1* (n=216)

pooled-os-5-year-ltb-desktop-2x
border line

With more than 146,000 patients treated worldwide to date†, TAFINLAR + MEKINIST is the most prescribed combination therapy for BRAF+ metastatic and adjuvant melanoma, making it the established leader in BRAF-targeted therapy.2

border line
*Low tumour burden is defined as normal LDH and <3 metastatic sites.
†As of August 2020
References: 1. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(1):626-636. 2. Data on file. Novartis Pharmaceuticals Corp; 2020.
Disclaimer: This is an international site for TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)  and is intended for healthcare professionals outside the US. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via www.novartisoncology.com/contact-novartis-oncology.jsp.
This site is intended for a global audience.
Novartis logo
© 2020 Novartis AG | Use of this website is subject to our Terms of Use

COVID-19 Update


Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4

ELIGIBILITY REQUIREMENTS

  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)
imgh22

Placebo (n=432)

STUDY ENDPOINTS

  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy